论文部分内容阅读
上海市多中心、开放性、自身比较，观察微粒化非诺贝特２００ｍｇ，每晚一次，治疗１３１例高脂血症病人４～８周的疗效和耐受性。男性７６例，女性５５例，平均年龄５６．２±９．７３岁，所属高血脂类型：Ⅱａ型２６例，Ⅱｂ型５３例，Ⅳ型５２例。治疗８周之后，Ⅱａ和Ⅱｂ型患者血清总胆固醇明显降低（平均降低２０％，Ｐ＜０．０１），Ⅱｂ和Ⅳ型患者血清甘油三酯明显降低（平均降低６０％～６３％，Ｐ＜０．０１），未出现严重不良反应，结论：微粒化非诺贝特特别适用于治疗Ⅱｂ和Ⅳ型高脂血症患者。４例合并有高尿酸血症者，治疗８周后，血尿酸平均降低５９％。
Shanghai multi-center, open, compared with their own, to observe the micronized fenofibrate 200mg, once night, the treatment of 131 cases of hyperlipidemia patients 4 to 8 weeks of efficacy and tolerance. There were 76 males and 55 females, with an average age of 56.2 ± 9.73 years. The type of hyperlipidemia was type Ⅱa in 26 cases, type Ⅱb in 53 cases and type Ⅳ in 52 cases. Serum total cholesterol was significantly decreased in Type IIa and Type IIb patients (mean 20%, P <0.01) after 8 weeks of treatment. Serum triglycerides were significantly decreased in Type IIb and Type IV patients (mean reduction 60% -63%, P < 0.01), no serious adverse reactions, the conclusion: micronized fenofibrate particularly suitable for the treatment of type IIb and type IV hyperlipidemia patients. 4 cases with hyperuricemia, treatment of 8 weeks, the average blood uric acid decreased 59%.